Clinical trial
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol
NCT01493531 is registered in ClinicalTrials.gov with Ardea Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol
- Lead sponsor
- Ardea Biosciences, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- July 31, 2014
- Enrollment
- 610 (actual)
- Sites
- 175
Conditions
As the registry lists them; a condition with its own page is linked.